SA55 Injection Phase II Study in the Treatment of Mild/Moderate COVID-19 Patients

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of Novel Coronavirus Broad-spectrum Neutralizing Antibody SA55 Injection in the Treatment of Mild/Moderate COVID-19 Patients

Evaluating the efficacy and safety of SA55 injection in light/medium COVID-19 patients

Study Overview

• Status: Recruiting
• Conditions: Infection of Upper Respiratory Tract Caused by 2019-nCoV
• Intervention / Treatment: Drug: SA55 Injection

• Study Type: Interventional
• Enrollment (Estimated): 150
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Guang Ning, M.D.; Phone Number: 13501656999; Email: guangning@medmail.com.cn

Study Locations

• China
  • Shanghai
    • Shanghai, Shanghai, China, 200025
      • Recruiting
      • Ruijin Hospital
      • Contact: Guang Ning; Phone Number: 13501656999; Email: guangning@medmail.com.cn
      • Principal Investigator: Guang Ning, M.D.
      • Principal Investigator: Qing Xie, M.D.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Male or female aged ≥ 18 years on the day of enrollment;
• On the day of enrollment, novel coronavirus nucleic acid test was positive and/or novel coronavirus antigen test was positive;
• On the day of enrollment, it meets the criteria for mild or medium COVID-19 cases, and the time from the first COVID-19 infection related symptoms is within 72 hours;
• Within 24 hours before enrollment, one or more of the following symptoms or signs must be present: a. fever, b. cough, c. sore throat, d. nasal congestion/runny nose, e. headache, f. muscle pain, g. shortness of breath/difficulty breathing, h. nausea, i. fatigue, j. vomiting, k. diarrhea;
• Subjects (male and female of childbearing age) and their sexual partners voluntarily take effective contraceptive measures within 6 months after signing the informed consent form and administering the experimental drug, and do not have plans to donate sperm or eggs;
• At rest, when inhaling air, the oxygen saturation is greater than 93%;
• Subjects voluntarily participate in the experiment and sign an informed consent form before the start of the study.

Exclusion Criteria:

• Individuals who are known to be allergic to the investigational drug, any component in the preparation, or other similar drugs;
• Individuals weighing less than 40 kg;
• There are comorbidities that require surgery within one month, or comorbidities that are considered life-threatening within one month;
• Before screening, he has received neutralizing antibody drugs from COVID-19, or received human immunoglobulin or convalescent plasma treatment from convalescent patients within 3 months, or received small molecule drugs from COVID-19 within 7 days;
• Suspected or confirmed to have combined serious and active bacterial, fungal, viral or other infections (except for COVID-19 infection), such as acute systemic infection, the researcher believes that intervention measures may pose a risk;
• Individuals who tested positive for influenza A/B virus antigens during screening;
• Plan to become pregnant within 6 months, already pregnant, or breastfeeding;
• Participated in clinical trials of other drugs or medical devices within 3 months prior to screening;
• Having/having suffered from severe neurological disorders (epilepsy, convulsions, or seizures) or mental illness, or having a family history of mental illness;
• Suffering from/having previously suffered from severe neurological diseases or other serious illnesses that the researcher has determined to be unsuitable for participation in the study (including but not limited to current systemic infections, uncontrolled autoimmune diseases, uncontrolled immunodeficiency diseases, history of myocardial infarction or heart disease, etc.);
• Unable to cooperate with the follow-up of the study, or unable to guarantee the non use of concomitant drugs/vaccines/treatments prohibited by this protocol during the study period (see section 6.4.2);
• The researcher believes that due to other reasons, it is not suitable to participate in this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: SA55 Injection; Group 1: 300 mg Group 2: 600 mg	Drug: SA55 Injection; Novel coronavirus broad-spectrum neutralizing antibody SA55 injection (SA55 injection) is developed and produced by Beijing Kexing Zhongwei Biologics Technology Co., Ltd. The main component of SA55 injection is novel coronavirus broad-spectrum neutralizing antibody SA55. Each milliliter contains 150 mg of novel coronavirus broad-spectrum neutralizing antibody SA55. Excipients include histidine hydrochloride, arginine hydrochloride, histidine hydrochloride, sucrose, and polysorbate 80 (II)
Placebo Comparator: Placebo; Group 1: 0 mg Group 2: 0 mg	Drug: SA55 Injection; Novel coronavirus broad-spectrum neutralizing antibody SA55 injection (SA55 injection) is developed and produced by Beijing Kexing Zhongwei Biologics Technology Co., Ltd. The main component of SA55 injection is novel coronavirus broad-spectrum neutralizing antibody SA55. Each milliliter contains 150 mg of novel coronavirus broad-spectrum neutralizing antibody SA55. Excipients include histidine hydrochloride, arginine hydrochloride, histidine hydrochloride, sucrose, and polysorbate 80 (II)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluation of the efficacy of SA55 injection in mild or moderate COVID-19 patients	Changes of novel coronavirus (SARS-CoV-2) load from baseline to D3, D5, D7	from baseline to D3, D5, D7

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluate the safety of SA55 injection in mild or moderate COVID-19 patients	The incidence of adverse events; The incidence of serious adverse events	an average of 1 year
Evaluation of the efficacy of SA55 injection in mild or moderate COVID-19 patients (impact on virological indicators)	(1) Changes in SARS-CoV-2 virus load relative to baseline at different time points; (2) Time to achieve continuous negative conversion of SARS-CoV-2 nucleic acid; (3) The proportion of subjects who achieved continuous negative SARS-CoV-2 nucleic acid conversion at different time points	(1) D9, D11, D15 (2) After administration (3) D3, D5, D7, D9, D11, D15
Evaluation of the efficacy of SA55 injection in mild or moderate COVID-19 patients (impact on clinical indicators)	Within 28 days after administration: the time of continuous disappearance of clinical symptoms and the time of continuous remission of clinical symptoms of 5, 7 and 11 COVID-19; The proportion of subjects who progress to severe/critically ill conditions; Hospitalization rate due to COVID-19; All cause mortality rate; Rescue treatment rate; Change of clinical symptom score of COVID-19 from baseline to different time points	an average of 1 year
Evaluate the pharmacokinetic characteristics of SA55 injection in mild or moderate COVID-19 patients	Serum pharmacokinetic parameters of SA55 after medication (peak time Tmax, peak concentration Cmax, area under the drug time curve AUC0-t, AUC0- ∞, elimination half-life t1/2, apparent clearance rate CL/F, apparent distribution volume Vd/F, etc.)	an average of 1 year
Evaluation of serum COVID-19 neutralizing activity at different time points	Serum pharmacokinetic parameters of SA55 after medication (peak time Tmax, peak concentration Cmax, area under the drug time curve AUC0-t, AUC0- ∞, elimination half-life t1/2, apparent clearance rate CL/F, apparent distribution volume Vd/F, etc.)	an average of 1 year
Evaluating the immunogenicity of SA55 injection	Serum anti drug antibody (ADA) levels at different time points	an average of 1 year

Collaborators and Investigators

• Sponsor: Sinovac Life Sciences Co., Ltd.
• Investigators: Principal Investigator: Guang Ning, Ruijin Hospital

Study record dates

Study Major Dates

• Study Start (Actual): August 31, 2023
• Primary Completion (Estimated): March 1, 2024
• Study Completion (Estimated): August 30, 2024

Study Registration Dates

• First Submitted: August 26, 2023
• First Submitted That Met QC Criteria: September 12, 2023
• First Posted (Actual): September 21, 2023

Study Record Updates

• Last Update Posted (Estimated): December 12, 2023
• Last Update Submitted That Met QC Criteria: December 11, 2023
• Last Verified: December 1, 2023

More Information

Terms related to this study

• Keywords: 2019-nCoV
• Other Study ID Numbers: PRO-SA55-2001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No